Tamibarotene
- Generic Name
- Tamibarotene
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25NO3
- CAS Number
- 94497-51-5
- Unique Ingredient Identifier
- 08V52GZ3H9
- Background
Tamibarotene is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
- Indication
Investigated for use/treatment in leukemia (unspecified).
Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia
Phase 1
Terminated
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 4
- Registration Number
- NCT00985530
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)
Phase 1
Completed
- Conditions
- Advanced Hepatocellular Carcinoma
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2012-07-03
- Lead Sponsor
- Zeria Pharmaceutical
- Target Recruit Count
- 43
- Registration Number
- NCT00731445
- Locations
- 🇯🇵
The University of Tokyo Hospital, Tokyo, Japan
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Phase 2
Completed
- Conditions
- Acute Promyelocytic Leukemia
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2013-02-13
- Lead Sponsor
- CytRx
- Target Recruit Count
- 15
- Registration Number
- NCT00520208
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath